Skip to content

Homepage

Author: Editas Medicine, Inc.

Posted Date:

May 28, 2026

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

Editas Medicine, Inc.

May 28, 2026
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

Editas Medicine, Inc.

May 26, 2026
Editas Medicine Announces Proposed Public Offering

Editas Medicine, Inc.

May 26, 2026
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress

Editas Medicine, Inc.

May 26, 2026
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

Editas Medicine, Inc.

May 14, 2026
Editas Medicine Announces First Quarter 2026 Results and Business Updates

Editas Medicine, Inc.

May 5, 2026
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

Editas Medicine, Inc.

April 27, 2026
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

Editas Medicine, Inc.

March 27, 2026
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Editas Medicine, Inc.

March 9, 2026
Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine, Inc.

February 23, 2026